[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608205":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":31,"centralContacts":43,"locations":49,"responsibleParty":63,"collaborators":67,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":73,"sex":79,"minAge":80,"maxAge":31,"enrollmentInfo":81,"targetDuration":31,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":52,"whyStopped":31,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Korea University Guro Hospital","OTHER",[8,15,21],{"label":9,"type":10,"description":11,"interventionNames":12},"Short DAPT","EXPERIMENTAL","Patients with optimized stent results confirmed by OCT will receive 1 month of dual antiplatelet therapy followed by clopidogrel monotherapy.",[13,14],"Drug: Short DAPT","Device: OCT-guided PCI",{"label":16,"type":17,"description":18,"interventionNames":19},"Standard DAPT","ACTIVE_COMPARATOR","Patients with suboptimal stent results (malapposition, dissection, under-expansion) with high bleeding risk will continue dual antiplatelet therapy for 6 months, according to guideline recommendations.",[20,14],"Drug: Standard DAPT",{"label":22,"type":17,"description":23,"interventionNames":24},"Extended DAPT","Patients with suboptimal stent results and high ischemic risk, as judged by the operator, will remain on dual antiplatelet therapy for 12 months.",[25,14],"Drug: Extended DAPT",[27,32,35,38],{"type":28,"name":9,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Patients receive aspirin and clopidogrel for 1 month after PCI. After 1 month, aspirin is discontinued and clopidogrel monotherapy is continued.",[9],null,{"type":28,"name":16,"description":33,"armGroupLabels":34,"otherNames":31},"Patients with high bleeding risk will receive aspirin and clopidogrel for 6 months after PCI (unoptimization confirmed in OCT), followed by single antiplatelet therapy thereafter.",[16],{"type":28,"name":22,"description":36,"armGroupLabels":37,"otherNames":31},"Patients (with stet unoptimazation results in OCT imaging) receive aspirin and clopidogrel for 12 months after PCI.",[22],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":31},"DEVICE","OCT-guided PCI","All patients undergo percutaneous coronary intervention with mandatory intravascular imaging using optical coherence tomography to assess stent optimization (expansion, apposition, dissection).",[22,9,16],[44],{"name":45,"role":46,"phone":47,"phoneExt":31,"email":48},"Soohyung Park, MD, PhD","CONTACT","+82-10-3105-3710","shp503@naver.com",[50],{"facility":51,"status":52,"city":53,"state":54,"zip":55,"country":56,"countryCode":31,"cosmosGeoPoint":57,"geoPoint":62,"contacts":31},"Cardiovascular Center, Department of Internal Medicine, Korea University Guro Hospital","RECRUITING","Seoul","Gurodong-ro, Guro-gu","148","South Korea",{"type":58,"coordinates":59},"Point",[60,61],126.9784,37.566,{"lat":61,"lon":60},{"type":64,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"PRINCIPAL_INVESTIGATOR","Park, Soohyung","Assistant Professor, Interventional Cardiologist",[68],{"name":69,"class":70},"Abbott","INDUSTRY","100608205","oct-guided-stent-optimization-for-short-duration-dual-antiplatelet-therapy-in-stable-angina-100608205",false,"NCT07198529","OCT-Guided Stent Optimization for Short-Duration Dual Antiplatelet Therapy in Stable Angina","Optical Coherence Tomography for Stent Optimization and Its Impact on Short-Duration Dual Antiplatelet Therapy: A Single-Center, Prospective, Exploratory Study","COMFORT-SHORT","Inclusion Criteria:\n\n* Patients who undergo PCI using a cobalt-chromium everolimus-eluting stent (CoCr-EES)\n* Diagnosis of stable angina\n* Ability and willingness to provide written informed consent approved by the Institutional Review Board (IRB), and to comply with the study protocol and clinical follow-up schedule\n* Age ≥ 19 years\n\nExclusion Criteria:\n\n* Patients diagnosed with acute coronary syndrome (ACS), including unstable angina or acute myocardial infarction\n* Contraindications to antiplatelet therapy or OCT imaging\n* Presence of lesions with severe stenosis, heavy calcification, or marked vessel tortuosity that prevent passage of a guidewire or catheter\n* Patients with previously implanted coronary stents in the target lesion","ALL","19 Years",{"count":82,"type":83},130,"ESTIMATED","INTERVENTIONAL",[86],"NA","This study aims to evaluate whether the use of optical coherence tomography (OCT), an advanced intravascular imaging tool, can improve stent implantation results and make it possible to shorten the duration of dual antiplatelet therapy (DAPT) in patients with stable angina who undergo percutaneous coronary intervention (PCI).\n\nPCI with drug-eluting stents is a standard treatment for patients with stable angina, and these patients are usually prescribed DAPT for 6 to 12 months to prevent stent thrombosis and other complications. However, extended use of DAPT increases the risk of bleeding, which can lead to significant medical problems, especially in patients with high bleeding risk.\n\nOCT provides detailed, high-resolution images of the coronary arteries and the implanted stents, allowing physicians to optimize stent expansion and positioning. By ensuring that the stent is well-placed and fully expanded, OCT guidance may lower the risk of complications, potentially reducing the need for prolonged DAPT.\n\nIn this prospective study, patients with stable angina who require stent implantation will be enrolled and treated with OCT-guided PCI followed by a short course of DAPT. Their outcomes will be compared with those managed using conventional strategies.\n\nThe primary goal of this trial is to determine whether OCT-guided stent optimization can safely support a short-duration DAPT strategy, thereby reducing bleeding risk without compromising protection against ischemic events such as restenosis, myocardial infarction, or stent thrombosis.",[89,90],"Stable Angina","Coronary Artery Disease",[92,93,94,95,96],"Optical coherence tomography","stable angina","dual antiplatelet therapy","stent optimization","percutaneous coronary intervention","2025-12-11",{"date":99,"type":100},"2025-12-17","ACTUAL",{"date":102,"type":100},"2025-09-30",{"date":104,"type":83},"2029-09",{"name":5,"class":6},1]